Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 1:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Octreotide LAR 30 MG Injection Clear all
Completed Phase 3 Interventional Results available

Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly

NCT00600886
View directory record Official record
Conditions
Acromegaly
Interventions
Pasireotide, Octreotide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
14
States / cities
Los Angeles, California • Stanford, California • Gainesville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 23, 2026, 1:23 AM EDT
Completed Phase 4 Interventional Results available

Vasoconstrictors as Alternatives to Albumin After Large-Volume Paracentesis (LVP) in Cirrhosis

NCT00108355
View directory record Official record
Conditions
Ascites, Cirrhosis
Interventions
Albumin, Intravenous Saline Infusion (Albumin placebo), Midodrine, Oral tablet (Midodrine placebo), Octreotide LAR, Saline injection (Octreotide LAR placebo), Large Volume Paracentesis
Drug · Procedure
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 5, 2014 · Synced Sep 23, 2026, 1:23 AM EDT
Terminated Phase 3 Interventional

Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome

NCT00092287
View directory record Official record
Conditions
Malignant Carcinoid Syndrome
Interventions
lanreotide Autogel (somatostatin analogue), Sandostatin long acting release (LAR) Depot (somatostatin analogue)
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 29, 2020 · Synced Sep 23, 2026, 1:23 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly

NCT01137682
View directory record Official record
Conditions
Acromegaly
Interventions
Pasireotide, octreotide LAR 30mg, lanreotide ATG 120mg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
4
States / cities
Ann Arbor, Michigan • Portland, Oregon • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Sep 23, 2026, 1:23 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease

NCT00690430
View directory record Official record
Conditions
Symptomatic Refractory Resistant Carcinoid Disease
Interventions
Pasireotide, Octreotide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
10
States / cities
Scottsdale, Arizona • Tucson, Arizona • Loma Linda, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2013 · Synced Sep 23, 2026, 1:23 AM EDT
Completed Phase 2 Interventional

Trial of Thalidomide, a- Interferon +/- Octreotide in Patients With Unresectable Hepatocellular Carcinoma

NCT00250796
View directory record Official record
Conditions
Liver, Cancer
Interventions
Thalidomide, alpha interferon, Thalidomide, interferon, Octreotide
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
2
States / cities
Albuquerque, New Mexico • Santa Fe, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 6, 2010 · Synced Sep 23, 2026, 1:23 AM EDT
Active, not recruiting Phase 3 Interventional

A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET

NCT05050942
View directory record Official record
Conditions
Gastro-enteropancreatic Neuroendocrine Tumor
Interventions
CAM2029, Octreotide LAR, Lanreotide ATG
Drug
Lead sponsor
Camurus AB
Industry
Eligibility
18 Years and older
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
15
States / cities
Phoenix, Arizona • Santa Monica, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 23, 2026, 1:23 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours

NCT01578239
View directory record Official record
Conditions
Carcinoid Tumor of the Small Bowel, Neuroendocrine Tumour
Interventions
Octreotide LAR, 177Lu-DOTA0-Tyr3-Octreotate
Drug
Lead sponsor
Advanced Accelerator Applications
Industry
Eligibility
18 Years and older
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
13
States / cities
Los Angeles, California • Palo Alto, California • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Sep 23, 2026, 1:23 AM EDT
Completed Phase 2 Interventional Results available

Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers

NCT01121939
View directory record Official record
Conditions
Neuroendocrine Carcinoma
Interventions
Bevacizumab, Pertuzumab, Sandostatin LAR® Depot
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
9
States / cities
Fort Myers, Florida • Orlando, Florida • Augusta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Sep 23, 2026, 1:23 AM EDT
Completed Phase 2 Interventional Results available

AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

NCT00427349
View directory record Official record
Conditions
Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Neoplastic Syndrome
Interventions
AMG 706, octreotide
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
112
States / cities
Berwyn, Illinois • Chicago, Illinois • Joliet, Illinois + 78 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2023 · Synced Sep 23, 2026, 1:23 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET

NCT03972488
View directory record Official record
Conditions
Gastro-enteropancreatic Neuroendocrine Tumor
Interventions
Lutathera, 30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot), 2.5% Lys-Arg sterile amino acid solution, High dose 60 mg octreotide long-acting repeatable
Drug
Lead sponsor
Advanced Accelerator Applications
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
6
States / cities
New Haven, Connecticut • Tampa, Florida • Iowa City, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Sep 23, 2026, 1:23 AM EDT
Terminated Phase 3 Interventional

Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients

NCT00642421
View directory record Official record
Conditions
Acromegaly
Interventions
C2L-OCT-01 PR, 10 or 20 mg, C2L-OCT-01 PR, 20 mg
Drug
Lead sponsor
Ambrilia Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
5
States / cities
Los Angeles, California • Stanford, California • Buffalo, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2010 · Synced Sep 23, 2026, 1:23 AM EDT
Completed Phase 4 Interventional Results available

Ultrasound Guided Octreotide LAR Injection in Acromegaly

NCT00552071
View directory record Official record
Conditions
Acromegaly
Interventions
Octreotide LAR 30 MG Injection
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Sep 23, 2026, 1:23 AM EDT
Completed Phase 2 Interventional Results available

RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma

NCT00113360
View directory record Official record
Conditions
Neuroendocrine Carcinoma, Islet Cell Carcinoma
Interventions
RAD001, Octreotide Depot
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 23, 2026, 1:23 AM EDT
Terminated Phase 3 Interventional

Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly

NCT00765323
View directory record Official record
Conditions
Acromegaly
Interventions
Octreotide Implant, Sandostatin LAR Depot
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
8
States / cities
Palo Alto, California • Denver, Colorado • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2013 · Synced Sep 23, 2026, 1:23 AM EDT